{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T17:05:54Z","timestamp":1777395954930,"version":"3.51.4"},"reference-count":105,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T00:00:00Z","timestamp":1678147200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2023,3,7]]},"abstract":"<jats:p>An estimated 6.5 million Americans aged 65 years or older have Alzheimer\u2019s disease (AD), which will grow to 13.8 million Americans by 2060. Despite the growing burden of dementia, no fundamental change in drug development for AD has been seen in\u200a&gt;\u200a20 years. Currently approved drugs for AD produce only modest symptomatic improvements in cognition with small effect sizes. A growing mismatch exists between the urgent need to develop effective drugs for symptomatic AD and the largely failed search for disease modification. The failure rate of clinical trials in AD is high overall, and in particular for disease-modifying therapies. Research efforts in AD have focused predominantly on amyloid-\u03b2 and tau pathologies, but limiting clinical research to these \u201cclassical hallmarks\u201d of the disease does not address the most urgent patient, caregiver, or societal needs. Rather, clinical research should consider the complex pathophysiology of AD. Innovative approaches are needed that provide outside-the-box thinking, and re-imagine trial design, interventions, and outcomes as well as progress in proteomics and fluid biomarker analytics for both diagnostics and disease monitoring. A new approach offering a highly specific, yet multi-pronged intervention that exerts positive modulation on the HGF\/MET neurotrophic system is currently being tested in mid-to-late-stage clinical trials in mild to moderate AD. Findings from such trials may provide data to support novel approaches for development of innovative drugs for treating AD at various disease stages, including among patients already symptomatic, and may offer benefits for other neurodegenerative diseases.<\/jats:p>","DOI":"10.3233\/jad-220871","type":"journal-article","created":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T11:52:46Z","timestamp":1673956366000},"page":"1-12","source":"Crossref","is-referenced-by-count":8,"title":["The Case for a Novel Therapeutic Approach to Dementia: Small Molecule Hepatocyte Growth Factor (HGF\/MET) Positive Modulators"],"prefix":"10.1177","volume":"92","author":[{"given":"Hans J.","family":"Moebius","sequence":"first","affiliation":[{"name":"Athira Pharma, Inc., Bothell, WA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin J.","family":"Church","sequence":"additional","affiliation":[{"name":"Athira Pharma, Inc., Bothell, WA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-220871_ref1","first-page":"700","article-title":"Alzheimer\u2019s disease facts and figures","volume":"18","author":"Alzheimer\u2019s Association","year":"2022","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-220871_ref2","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","article-title":"Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: An analysis for the Global Burden of Disease Study 2019","volume":"7","author":"GBD 2019 Dementia Forecasting Collaborators","year":"2022","journal-title":"Lancet Public Health"},{"key":"10.3233\/JAD-220871_ref3","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer\u2019s disease","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"key":"10.3233\/JAD-220871_ref4","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s40120-022-00338-8","article-title":"The humanistic and economic burden of Alzheimer\u2019s disease","volume":"11","author":"Tahami Monfared","year":"2022","journal-title":"Neurol Ther"},{"key":"10.3233\/JAD-220871_ref5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2022","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-220871_ref6","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.neurobiolaging.2010.04.024","article-title":"The dynamics of Alzheimer\u2019s disease biomarkers in the Alzheimer\u2019s Disease Neuroimaging Initiative cohort","volume":"31","author":"Caroli","year":"2010","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-220871_ref7","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s10654-017-0326-z","article-title":"Temporal association patterns and dynamics of amyloid-\u03b2 and tau in Alzheimer\u2019s disease","volume":"33","author":"Ower","year":"2018","journal-title":"Eur J Epidemiol"},{"key":"10.3233\/JAD-220871_ref8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3389\/fneur.2012.00073","article-title":"Behavioral and psychological symptoms of dementia","volume":"3","author":"Cerejeira","year":"2012","journal-title":"Front Neurol"},{"key":"10.3233\/JAD-220871_ref9","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/14737167.2017.1313118","article-title":"Direct and indirect cost of managing Alzheimer\u2019s disease and related dementias in the United States","volume":"17","author":"Deb","year":"2017","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.3233\/JAD-220871_ref10","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3233\/JAD-190426","article-title":"Tip of the iceberg: Assessing the global socioeconomic costs of Alzheimer\u2019s disease and related dementias and strategic implications for stakeholders","volume":"70","author":"El-Hayek","year":"2019","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-220871_ref11","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13195-022-00969-x","article-title":"Economic and caregiver impact of Alzheimer\u2019s disease across the disease spectrum: A cohort study","volume":"14","author":"Dauphinot","year":"2022","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-220871_ref12","first-page":"S177","article-title":"Economic burden of Alzheimer disease and managed care considerations","volume":"26(8 Suppl)","author":"Wong","year":"2020","journal-title":"Am J Manag Care"},{"key":"10.3233\/JAD-220871_ref13","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s10198-014-0620-6","article-title":"Costs of care for people with dementia just before and after nursing home placement: Primary data from eight European countries","volume":"16","author":"W\u00fcbker","year":"2015","journal-title":"Eur J Health Econ"},{"key":"10.3233\/JAD-220871_ref14","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1186\/s12913-021-07017-8","article-title":"Predictors of institutionalization in users of day care facilities with mild cognitive impairment to moderate dementia","volume":"21","author":"Spiegl","year":"2021","journal-title":"BMC Health Serv Res"},{"key":"10.3233\/JAD-220871_ref15","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jalz.2009.01.028","article-title":"Early identification and treatment of Alzheimer\u2019s disease: Social and fiscal outcomes","volume":"5","author":"Weimer","year":"2009","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-220871_ref16","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/gps.2141","article-title":"Treatment with galantamine and time to nursing home placement in Alzheimer\u2019s disease patients with and without cerebrovascular disease","volume":"24","author":"Feldman","year":"2009","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.3233\/JAD-220871_ref17","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2174\/1567205015666180507105326","article-title":"Short-term response to cholinesterase inhibitors in Alzheimer\u2019s disease delays time to nursing home placement","volume":"15","author":"Wattmo","year":"2018","journal-title":"Curr Alzheimer Res"},{"key":"10.3233\/JAD-220871_ref18","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/00019053-200321050-00004","article-title":"Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer\u2019s disease","volume":"21","author":"Wimo","year":"2003","journal-title":"Pharmacoeconomics"},{"key":"10.3233\/JAD-220871_ref19","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2147\/ciia.2006.1.2.143","article-title":"Economic considerations in the management of Alzheimer\u2019s disease","volume":"1","author":"Zhu","year":"2006","journal-title":"Clin Interv Aging"},{"key":"10.3233\/JAD-220871_ref20","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1212\/01.wnl.0000242727.81172.91","article-title":"Improving caregiver well-being delays nursing home placement of patients with Alzheimer disease","volume":"67","author":"Mittelman","year":"2006","journal-title":"Neurology"},{"key":"10.3233\/JAD-220871_ref21","first-page":"e12159","article-title":"Projection of budgetary savings to US state Medicaid programs from reduced nursing home use due to an Alzheimer\u2019s disease treatment","volume":"13","author":"Lam","year":"2021","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-220871_ref22","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/alz.12578","article-title":"Projecting the long-term societal value of a disease-modifying treatment for Alzheimer\u2019s disease in the United States","volume":"18","author":"Prados","year":"2022","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-220871_ref23","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/cns.12484","article-title":"Role of donepezil in the management of neuropsychiatric symptoms in Alzheimer\u2019s disease and dementia with Lewy bodies","volume":"22","author":"Cummings","year":"2016","journal-title":"CNS Neurosci Ther"},{"key":"10.3233\/JAD-220871_ref24","first-page":"741059","article-title":"Prevalence of behavioral and psychological symptoms of dementia in community-dwelling dementia patients: A systematic review","volume":"12","author":"Kwon","year":"2021","journal-title":"Psychiatry"},{"key":"10.3233\/JAD-220871_ref25","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1159\/000481568","article-title":"Behavioural and psychological symptoms of dementia: Correlates and impact on caregiver distress","volume":"7","author":"Mukherjee","year":"2017","journal-title":"Dement Geriatr Cogn Dis Extra"},{"key":"10.3233\/JAD-220871_ref26","doi-asserted-by":"crossref","first-page":"e190828","DOI":"10.1001\/jamanetworkopen.2019.0828","article-title":"Assessment of reported comparative effectiveness and safety of atypical antipsychotics in the treatment of behavioral and psychological symptoms of dementia: A network meta-analysis","volume":"2","author":"Yunusa","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.3233\/JAD-220871_ref27","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13024-021-00424-9","article-title":"New approaches to symptomatic treatments for Alzheimer\u2019s disease","volume":"16","author":"Cummings","year":"2021","journal-title":"Neurodegener"},{"key":"10.3233\/JAD-220871_ref28","first-page":"160","article-title":"Behavioural and psychological symptoms of dementia in patients with Alzheimer\u2019s disease and family caregiver burden: A path analysis","volume":"21","author":"Kim","year":"2021","journal-title":"Geriatr"},{"key":"10.3233\/JAD-220871_ref29","doi-asserted-by":"crossref","first-page":"101212","DOI":"10.1016\/j.arr.2020.101212","article-title":"Beta-amyloid: The known unknowns","volume":"65","author":"Ayton","year":"2021","journal-title":"Ageing Res Rev"},{"key":"10.3233\/JAD-220871_ref30","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41583-021-00533-w","article-title":"The probabilistic model of Alzheimer disease: The amyloid hypothesis revised","volume":"23","author":"Frisoni","year":"2022","journal-title":"Nat Rev Neurosci"},{"key":"10.3233\/JAD-220871_ref31","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/NRL.0000000000000320","article-title":"Alzheimer disease clinical trials targeting amyloid: Lessons learned from success in mice and failure in humans","volume":"26","author":"Reiss","year":"2021","journal-title":"Neurologist"},{"key":"10.3233\/JAD-220871_ref32","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.trci.2018.11.004","article-title":"FDA position statement \u201cEarly Alzheimer\u2019s disease: Developing drugs for treatment, Guidance for Industry\u201d","volume":"5","author":"Sabbagh","year":"2019","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-220871_ref35","first-page":"CD003154","article-title":"Memantine for dementia","volume":"3","author":"McShane","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.3233\/JAD-220871_ref36","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1136\/jnnp.2003.029074","article-title":"Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer\u2019s disease","volume":"75","author":"Rockwood","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JAD-220871_ref37","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/gps.1341","article-title":"Effects of memantine on behavioural symptoms in Alzheimer\u2019s disease patients: An analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies","volume":"20","author":"Gauthier","year":"2005","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.3233\/JAD-220871_ref38","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13195-019-0529-5","article-title":"The \u201crights\u201d of precision drug development for Alzheimer\u2019s disease","volume":"11","author":"Cummings","year":"2019","journal-title":"Alzheimers Res Therapy"},{"key":"10.3233\/JAD-220871_ref39","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41386-020-00840-3","article-title":"Systems-based proteomics to resolve the biology of Alzheimer\u2019s disease beyond amyloid and tau","volume":"46","author":"Rayaprolu","year":"2021","journal-title":"Neuropsychopharmacology"},{"key":"10.3233\/JAD-220871_ref40","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s13195-021-00927-z","article-title":"The Alzheimer\u2019s disease drug development landscape","volume":"13","author":"van Bokhoven","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-220871_ref41","doi-asserted-by":"crossref","first-page":"8769","DOI":"10.3390\/ijms22168769","article-title":"Deconstructing Alzheimer\u2019s disease: How to bridge the gap between experimental models and the human pathology?","volume":"22","author":"Vignon","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.3233\/JAD-220871_ref42","doi-asserted-by":"crossref","first-page":"694329","DOI":"10.3389\/fneur.2021.694329","article-title":"Methodological issues in randomized clinical trials for prodromal Alzheimer\u2019s and Parkinson\u2019s disease","volume":"12","author":"de Aquino","year":"2021","journal-title":"Front Neurol"},{"key":"10.3233\/JAD-220871_ref43","first-page":"306","article-title":"Platform trials to expedite drug development in Alzheimer\u2019s disease: A report from the EU\/US CTAD Task Force","volume":"8","author":"Aisen","year":"2021","journal-title":"J Prev Alzheimers Dis"},{"key":"10.3233\/JAD-220871_ref44","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.3233\/JAD-179901","article-title":"Clinical trials for disease-modifying therapies in Alzheimer\u2019s disease: A primer, lessons learned, and a blueprint for the future","volume":"64","author":"Cummings","year":"2018","journal-title":"Alzheimers Dis"},{"key":"10.3233\/JAD-220871_ref45","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00002093-199601031-00009","article-title":"Observations and suggestions on antidementia drug development","volume":"10","author":"Leber","year":"1996","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.3233\/JAD-220871_ref46","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13195-016-0207-9","article-title":"Drug development in Alzheimer\u2019s disease: The path to 2025","volume":"8","author":"Cummings","year":"2016","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-220871_ref47","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","article-title":"A\/T\/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers","volume":"87","author":"Jack","year":"2016","journal-title":"Neurology"},{"key":"10.3233\/JAD-220871_ref48","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3233\/JAD-191227","article-title":"The amyloid, tau, and neurodegeneration (A\/T\/N) classification applied to a clinical research cohort with long-term follow-up","volume":"74","author":"Gr\u00f8ntvedt","year":"2020","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-220871_ref49","doi-asserted-by":"crossref","first-page":"718959","DOI":"10.3389\/fnagi.2021.718959","article-title":"Optimal combinations of AT(N) biomarkers to determine longitudinal cognition in the Alzheimer\u2019s disease","volume":"13","author":"Lin","year":"2021","journal-title":"Front Aging Neurosci"},{"key":"10.3233\/JAD-220871_ref50","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41582-021-00520-w","article-title":"Developing the ATX(N) classification for use across the Alzheimer disease continuum","volume":"17","author":"Hampel","year":"2021","journal-title":"Nat Rev Neurol"},{"key":"10.3233\/JAD-220871_ref51","doi-asserted-by":"crossref","first-page":"37","DOI":"10.14336\/AD.2021.0529","article-title":"The cause of Alzheimer\u2019s disease: The theory of multipathology convergence to chronic neuronal stress","volume":"13","author":"Decourt","year":"2022","journal-title":"Aging Dis"},{"key":"10.3233\/JAD-220871_ref52","first-page":"769","article-title":"Large-scale proteomic analysis of Alzheimer\u2019s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation","volume":"26","author":"Johnson","year":"2020","journal-title":"Med"},{"key":"10.3233\/JAD-220871_ref53","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41572-021-00269-y","article-title":"Alzheimer disease","volume":"7","author":"Knopman","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.3233\/JAD-220871_ref54","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3390\/bioengineering8120211","article-title":"Alzheimer\u2019s disease: Current perspectives and advances in physiological modeling","volume":"8","author":"Boder","year":"2021","journal-title":"Bioengineering"},{"key":"10.3233\/JAD-220871_ref55","doi-asserted-by":"crossref","first-page":"eaaz9360","DOI":"10.1126\/sciadv.aaz9360","article-title":"Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer\u2019s disease","volume":"6","author":"Higginbotham","year":"2020","journal-title":"Sci Adv"},{"key":"10.3233\/JAD-220871_ref56","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/d41573-020-00217-7","article-title":"Failure of first anti-tau antibody in Alzheimer disease highlights risks of history repeating","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.3233\/JAD-220871_ref57","first-page":"5380346","article-title":"Clinical trials in Alzheimer\u2019s disease: A hurdle in the path of remedy","volume":"2020","author":"Oxford","year":"2020","journal-title":"Int J Alzheimers Dis"},{"key":"10.3233\/JAD-220871_ref58","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S1474-4422(21)00066-1","article-title":"Clinical diagnosis of Alzheimer\u2019s disease: Recommendations of the International Working Group","volume":"20","author":"Dubois","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-220871_ref59","doi-asserted-by":"crossref","first-page":"e2454","DOI":"10.1212\/WNL.0000000000200304","article-title":"Trajectories of cognitive decline in brain donors with autopsy-confirmed Alzheimer disease and cerebrovascular disease","volume":"98","author":"Frank","year":"2022","journal-title":"Neurology"},{"key":"10.3233\/JAD-220871_ref60","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3389\/fnins.2018.00025","article-title":"Reconsideration of amyloid hypothesis and tau hypothesis in Alzheimer\u2019s disease","volume":"12","author":"Kametani","year":"2018","journal-title":"Front Neurosci"},{"key":"10.3233\/JAD-220871_ref61","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3233\/ADR-200260","article-title":"Does informant-based reporting of cognitive decline correlate with age-adjusted hippocampal volume in mild cognitive impairment and Alzheimer\u2019s disease?","volume":"5","author":"Sabbagh","year":"2021","journal-title":"J Alzheimers Dis Rep"},{"key":"10.3233\/JAD-220871_ref62","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/cts.12491","article-title":"Lessons learned from Alzheimer disease: Clinical trials with negative outcomes","volume":"11","author":"Cummings","year":"2018","journal-title":"Clin Transl Sci"},{"key":"10.3233\/JAD-220871_ref63","doi-asserted-by":"crossref","unstructured":"Herrup K (2022) Fallacies in neuroscience: The Alzheimer\u2019s Edition. eNeuro 9, ENEURO.0530-21.2021.","DOI":"10.1523\/ENEURO.0530-21.2021"},{"key":"10.3233\/JAD-220871_ref64","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/NEN.0000000000000052","article-title":"Mild cognitive impairment and asymptomatic Alzheimer disease subjects: Equivalent \u03b2-amyloid and tau loads with divergent cognitive outcomes","volume":"73","author":"Iacono","year":"2014","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.3233\/JAD-220871_ref65","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1093\/brain\/awt171","article-title":"Dissecting phenotypic traits linked to human resilience to Alzheimer\u2019s pathology","volume":"136","author":"Perez-Nievas","year":"2013","journal-title":"Brain"},{"key":"10.3233\/JAD-220871_ref66","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419844113","article-title":"Advances in cerebral amyloid angiopathy imaging","volume":"12","author":"Chen","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"key":"10.3233\/JAD-220871_ref67","first-page":"109","article-title":"An integrated view on vascular dysfunction in Alzheimer\u2019s disease","volume":"19","author":"Klohs","year":"2019","journal-title":"Dis"},{"key":"10.3233\/JAD-220871_ref68","doi-asserted-by":"crossref","first-page":"101483","DOI":"10.1016\/j.arr.2021.101483","article-title":"Interactions between glial cells and the blood-brain barrier and their role in Alzheimer\u2019s disease","volume":"72","author":"Zhao","year":"2021","journal-title":"Ageing Res Rev"},{"key":"10.3233\/JAD-220871_ref69","doi-asserted-by":"crossref","DOI":"10.1177\/1179573517709278","article-title":"Tumor necrosis factor \u03b1 inhibition for Alzheimer\u2019s disease","volume":"9","author":"Chang","year":"2017","journal-title":"J Cent Nerv Syst Dis"},{"key":"10.3233\/JAD-220871_ref70","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.3233\/JAD-220569","article-title":"It\u2019s groundhog day! What can the history of science say about the crisis in Alzheimer\u2019s disease research?","volume":"90","author":"Jacobs","year":"2022","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-220871_ref71","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s13311-022-01185-z","article-title":"Heterogeneity in Alzheimer\u2019s disease diagnosis and progression rates: Implications for therapeutic trials","volume":"19","author":"Duara","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.3233\/JAD-220871_ref72","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3390\/biomedicines7040097","article-title":"Reasons for failed trials of disease-modifying treatments for Alzheimer disease and their contribution in recent research","volume":"7","author":"Yiannopoulou","year":"2019","journal-title":"Biomedicines"},{"key":"10.3233\/JAD-220871_ref73","first-page":"134","article-title":"The Integrated Alzheimer\u2019s Disease Rating Scale (iADRS) Findings from the EXPEDITION3 Trial","volume":"5","author":"Wessels","year":"2018","journal-title":"J Prev Alzheimers Dis"},{"key":"10.3233\/JAD-220871_ref74","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1136\/jnnp-2015-312383","article-title":"ADCOMS: A composite clinical outcome for prodromal Alzheimer\u2019s disease trials","volume":"87","author":"Wang","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JAD-220871_ref75","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.2307\/2531158","article-title":"Procedures for comparing samples with multiple endpoints","volume":"40","author":"O\u2019Brien","year":"1984","journal-title":"Biometrics"},{"key":"10.3233\/JAD-220871_ref78","unstructured":"Food and Drug Administration Guidance for Industry (2018) Early Alzheimer\u2019s Disease: Developing Drugs for Treatment."},{"key":"10.3233\/JAD-220871_ref79","doi-asserted-by":"crossref","first-page":"156","DOI":"10.2174\/157436211795659982","article-title":"Hepatocyte growth factor (HGF): Neutrophic functions and therapeutic implications for neuronal injury\/disease","volume":"6","author":"Funakoshi","year":"2011","journal-title":"Curr Signal Tranduct Ther"},{"key":"10.3233\/JAD-220871_ref80","doi-asserted-by":"crossref","first-page":"683609","DOI":"10.3389\/fcell.2021.683609","article-title":"HGF and MET: From brain development to neurological disorders","volume":"9","author":"Desole","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.3233\/JAD-220871_ref81","doi-asserted-by":"crossref","first-page":"588","DOI":"10.2183\/pjab.86.588","article-title":"The discovery of hepatocyte growth factor (HGF) and its significance for cell biology, life sciences and clinical medicine","volume":"86","author":"Nakamura","year":"2010","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"10.3233\/JAD-220871_ref82","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1440-1746.2010.06549.x","article-title":"Hepatocyte growth factor twenty years on: Much more than a growth factor","volume":"26 Suppl 1","author":"Nakamura","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"key":"10.3233\/JAD-220871_ref83","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.expneurol.2007.10.001","article-title":"Hepatocyte growth factor improves synaptic localization of the NMDA receptor and intracellular signaling after excito- toxic injury in cultured hippocampal neurons","volume":"210","author":"Akita","year":"2008","journal-title":"Exp Neurol"},{"key":"10.3233\/JAD-220871_ref84","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/6310","article-title":"Hepatocyte growth factor, a versatile signal for developing neurons","volume":"2","author":"Maina","year":"1999","journal-title":"Nat Neurosci"},{"key":"10.3233\/JAD-220871_ref85","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1634\/stemcells.2008-0226","article-title":"Endogenous hepatocyte growth factor is a niche signal for subventricular zone neural stem cell amplification and self-renewal","volume":"27","author":"Nicoleau","year":"2009","journal-title":"Stem Cells"},{"key":"10.3233\/JAD-220871_ref86","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.4161\/cc.5.14.2918","article-title":"The receptor tyrosine kinase Met and its ligand hepatocyte growth factor are clustered at excitatory synapses and can enhance clustering of synaptic proteins","volume":"5","author":"Tyndall","year":"2006","journal-title":"Cell Cycle"},{"key":"10.3233\/JAD-220871_ref87","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/0006-8993(94)91250-5","article-title":"Immunohistochemistry with antibodies to hepatocyte growth factor and its receptor protein (c-MET) in human brain tissues","volume":"637","author":"Yamada","year":"1004","journal-title":"Brain Res"},{"key":"10.3233\/JAD-220871_ref88","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0169-328X(02)00168-7","article-title":"Localization and functional role of hepatocyte growth factor (HGF) and its receptor c-met in the rat developing cerebral cortex","volume":"103","author":"Sun","year":"2002","journal-title":"Brain Res Mol Brain Res"},{"key":"10.3233\/JAD-220871_ref89","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.neuroscience.2004.06.031","article-title":"Hepatocyte growth factor as an enhancer of NMDA currents and synaptic plasticity in the hippocampus","volume":"128","author":"Akimoto","year":"2004","journal-title":"Neuroscience"},{"key":"10.3233\/JAD-220871_ref90","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1161\/01.HYP.0000208598.57687.3e","article-title":"Gene transfer of hepatocyte growth factor gene improves learning and memory in the chronic stage of cerebral infarction","volume":"47","author":"Shimamura","year":"2006","journal-title":"Hypertension"},{"key":"10.3233\/JAD-220871_ref91","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/sj.gt.3303094","article-title":"Alleviation of A\u03b2-induced cognitive impairment by ultrasound-mediated gene transfer of HGF in a mouse model","volume":"15","author":"Takeuchi","year":"2008","journal-title":"Gene Therapy"},{"key":"10.3233\/JAD-220871_ref92","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jns.2012.12.009","article-title":"Mesenchymal stem cell transplantation in multiple sclerosis","volume":"333","author":"Cohen","year":"2013","journal-title":"J Neurol Sci"},{"key":"10.3233\/JAD-220871_ref93","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/jcbfm.2010.211","article-title":"Acute hepatocyte growth factor treatment induces long-term neuroprotection and stroke recovery via mechanisms involving neural precursor cell proliferation and differentiation","volume":"31","author":"Doeppner","year":"2011","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.3233\/JAD-220871_ref94","doi-asserted-by":"crossref","first-page":"e27706","DOI":"10.1371\/journal.pone.0027706","article-title":"Human hepatocyte growth factor promotes functional recovery in primates after spinal cord injury","volume":"6","author":"Kitamura","year":"2011","journal-title":"PLoS One"},{"key":"10.3233\/JAD-220871_ref95","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/sj.gt.3302810","article-title":"Prevention of onset of Parkinson\u2019s disease by gene transfer of human hepatocyte growth factor in rodent model: A model of gene therapy for Parkinson\u2019s disease","volume":"13","author":"Koike","year":"2006","journal-title":"Gene Therapy"},{"key":"10.3233\/JAD-220871_ref96","doi-asserted-by":"crossref","first-page":"6537","DOI":"10.1523\/JNEUROSCI.22-15-06537.2002","article-title":"Overexpression of HGF retards disease progression and prolongs life span in a transgenic mouse model of ALS","volume":"22","author":"Sun","year":"2002","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-220871_ref97","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0006-8993(97)00958-X","article-title":"Hepatocyte growth factor (HGF\/SF) in Alzheimer\u2019s disease","volume":"779","author":"Fenton","year":"1998","journal-title":"Brain Res"},{"key":"10.3233\/JAD-220871_ref98","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1034\/j.1600-0404.2003.02089.x","article-title":"Increased hepatocyte growth factor level in cerebrospinal fluid in Alzheimer\u2019s disease","volume":"107","author":"Tsuboi","year":"2003","journal-title":"Acta Neurol Scand"},{"key":"10.3233\/JAD-220871_ref99","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1186\/s12883-021-02356-9","article-title":"Associations of the cerebrospinal fluid hepatocyte growth factor with Alzheimer\u2019s disease pathology and cognitive function","volume":"21","author":"Zhao","year":"2021","journal-title":"BMC Neurol"},{"key":"10.3233\/JAD-220871_ref100","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/neup.12095","article-title":"Down-regulation of MET in hippocampal neurons of Alzheimer\u2019s disease brains","volume":"34","author":"Hamasaki","year":"2014","journal-title":"Neuropathology"},{"key":"10.3233\/JAD-220871_ref101","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.neurobiolaging.2005.09.034","article-title":"The amyloid pathology progresses in a neurotransmitter-specific manner","volume":"27","author":"Bell","year":"2006","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-220871_ref102","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3389\/fnins.2019.00735","article-title":"Targeting the synapse in Alzheimer\u2019s disease","volume":"13","author":"Jackson","year":"2019","journal-title":"Front Neurosci"},{"key":"10.3233\/JAD-220871_ref103","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00401-011-0884-1","article-title":"Mild cognitive impairment: Pathology and mechanisms","volume":"123","author":"Mufson","year":"2012","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JAD-220871_ref104","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1126\/science.1074069","article-title":"Alzheimer\u2019s disease is a synaptic failure","volume":"298","author":"Selkoe","year":"2002","journal-title":"Science"},{"issue":"Suppl 10","key":"10.3233\/JAD-220871_ref106","doi-asserted-by":"crossref","first-page":"e065874","DOI":"10.1002\/alz.065874","article-title":"Fosgonimeton, a novel, small molecule positive modulator of the HGF\/MET system is neuroprotective in primary neuron culture","volume":"18","author":"Reda","year":"2022","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-220871_ref107","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3233\/JAD-215511","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of the positive modulator of HGF\/MET, fosgonimeton, in healthy volunteers and subjects with Alzheimer\u2019s disease: Randomized, placebo-controlled, double-blind, phase I clinical trial","volume":"86","author":"Hua","year":"2022","journal-title":"J Alzheimers Dis"},{"issue":"Suppl 10","key":"10.3233\/JAD-220871_ref109","doi-asserted-by":"crossref","first-page":"e061572","DOI":"10.1002\/alz.061572","article-title":"ACT-AD: Fosgonimeton in mild-to-moderate Alzheimer\u2019s disease \u2013First results of a randomized, placebo-controlled, 26-week Phase 2 proof-of-concept trial","volume":"18","author":"Moebius","year":"2022","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-220871_ref110","doi-asserted-by":"crossref","first-page":"2104880","DOI":"10.1155\/2022\/2104880","article-title":"Predictive power of cognitive biomarkers in neurodegenerative disease drug development: Utility of the P300 event-related potential","volume":"2022","author":"Olichney","year":"2022","journal-title":"Neural Plast"},{"key":"10.3233\/JAD-220871_ref111","doi-asserted-by":"crossref","first-page":"101346","DOI":"10.1016\/j.arr.2021.101346","article-title":"Omics sciences for systems biology in Alzheimer\u2019s disease: State-of-the-art of the evidence","volume":"69","author":"Hampel","year":"2021","journal-title":"Ageing Res Rev"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-220871","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:07:11Z","timestamp":1777370831000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-220871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,7]]},"references-count":105,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.3233\/jad-220871","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,7]]}}}